Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779174 | 0.85 | PKM (0.64) | TP53ALDH1A1KMT2ALMNA | |
| SCHEMBL24025469 | 0.85 | CHRM5 (0.60) | CHRM5ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL24025520 | 0.80 | CHRM1 (0.54) | CHRM5ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL24025372 | 0.80 | CHRM1 (0.54) | CHRM5ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL24025490 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL10154252 | 0.78 | ALDH1A1 (0.69) | EPHX2TP53ALDH1A1MAPTKMT2A | |
| SCHEMBL30597550 | 0.77 | MEN1 (0.59) | EPHX2CHRM5ALDH1A1MAPTKMT2A | |
| SCHEMBL30597504 | 0.77 | MAPT (0.63) | CHRM5ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL24058352 | 0.76 | AOC2 (0.48) | EPHX2 | |
| SCHEMBL24025497 | 0.76 | AOC2 (0.48) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | EPHX2 1579/4885CHRM5 788/4885TP53 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.